You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
For over 25 years, Medtronic has been a global leader in deep brain stimulation (DBS) device design and development. And today, more than 175,000 Medtronic DBS devices* have been implanted to treat Parkinson’s disease, epilepsy, essential tremor and dystonia.
View clinical research, understand patient selection, and discover why DBS is an important addition to the treatment continuum for the following indications.
DBS may be a therapeutic option for patients with recent or longer-standing motor complications.
DBS FOR PARKINSON'SMedtronic DBS for epilepsy gives patients a flexible, accessible therapy option that offers safe and effective1 seizure control.
DBS FOR EPILEPSYLearn more about out how DBS works and how to identify candidates.
DBS FOR ESSENTIAL TREMORDBS may be considered when chronic, primary dystonia symptoms can’t be successfully managed with medication.
DBS FOR DYSTONIASpeak to your local Medtronic
representative to learn more about
Medtronic deep brain stimulation.
Number of unique patients implanted (i.e “new patients”)
Salanova V, Witt T, Worth R et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology 2015;84(10):1017-1025.